4.4 Review

Immunization of high-risk paediatric populations: Central European Vaccination Awareness Group recommendations

期刊

EXPERT REVIEW OF VACCINES
卷 13, 期 6, 页码 801-815

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.2014.897615

关键词

Central Europe; high-risk; immunization; paediatric; recommendations

资金

  1. GSK
  2. Apogepha
  3. Ferring
  4. Pfizer
  5. Nestle
  6. Wyeth Lederle
  7. sanofi aventis
  8. Merck Sharp Dohme (MSD)
  9. Sanofi Pasteur
  10. MSD
  11. Novartis
  12. Baxter
  13. GSK Slovenia
  14. PharmaSwiss Slovenia
  15. Aventis Pasteur
  16. PharmaSwiss
  17. Merck
  18. Wyeth
  19. Abbott
  20. GlaxoSmithKline

向作者/读者索取更多资源

Over the last decade, childhood immunization has substantially reduced morbidity and mortality from vaccine-preventable diseases. However, particular paediatric risk groups, such as those with comorbidities, may not be adequately vaccinated despite being more susceptible to complications and death from certain infectious diseases. This may be due to lack of immunization recommendations, lack of awareness, or incomplete adherence to existing guidelines. Furthermore, recommendations for immunization can be inconsistent across Europe. An expanded initiative from the Central European Vaccination Awareness Group aims to raise awareness of the different high-risk paediatric groups, differentiate them according to their specific risk, and formalise a guidance statement for the immunization of each population.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据